S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com -- Neuralink has received approval to begin its first clinical study in Great Britain, called GB-PRIME, the company announced on Thursday.
The brain-computer interface (BCI) developer secured approvals from the Medicines and Healthcare products Regulatory Agency, the Health Research Authority and Health and Care Research Wales, and the London – Camberwell St Giles Research Ethics Committee.
The clinical study will evaluate the safety of Neuralink’s fully-implantable, wireless brain-computer interface and surgical robot, while also assessing the initial functionality of the technology. The BCI is designed to allow people with severe paralysis to control devices and interact with the digital world using only their thoughts.
GB-PRIME will be conducted at two locations: University College London Hospitals NHS Foundation Trust and The Newcastle upon Tyne Hospitals NHS Foundation Trust. The study builds on Neuralink’s ongoing PRIME trial in the United States.
The company is currently recruiting participants who are residents of Great Britain with limited or no ability to use both hands due to conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injury, or other neurological disorders.
Interested individuals can join Neuralink’s Patient Registry and learn more about the trial through the company’s website.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.